Eric Sigler, MD
Ophthalmology · Massapequa, NYNPI 1447427067
Payments from drug & device makers
Across 450 payments — averaging $1074.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$274K
- Genentech, Inc.$134K
- Regeneron Healthcare Solutions, Inc.$52K
- Eyepoint US, Inc.$12K
- Mallinckrodt Enterprises LLC$4K
- Genentech USA, Inc.$3K
- plus $5K from 24 others
What the payments were for
- Consulting fees$8,9703%
- Speaking & faculty fees$328,16294%
- Travel & lodging$5870%
- Food & beverage$11,7363%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 144 | $274,259 |
| Genentech, Inc. | 27 | $134,007 |
| Regeneron Healthcare Solutions, Inc. | 77 | $51,740 |
| Eyepoint US, Inc. | 22 | $11,503 |
| Mallinckrodt Enterprises LLC | 16 | $3,837 |
| Genentech USA, Inc. | 42 | $3,342 |
| Alimera Sciences, Inc. | 10 | $1,563 |
| Astellas Pharma US Inc | 16 | $556 |
| ANI Pharmaceuticals, Inc. | 17 | $402 |
| Biotissue Holdings Inc. | 12 | $390 |
| AbbVie(2 entities) | 13 | $302 |
| Apellis Pharmaceuticals, Inc. | 8 | $270 |
| Sun Pharmaceutical Industries Inc. | 6 | $221 |
| Oculus Surgical Inc. | 2 | $183 |
| Harrow Eye, LLC | 5 | $147 |
| Novartis | 8 | $129 |
| Dompe US, Inc. | 1 | $122 |
| Bausch & Lomb Americas Inc. | 4 | $89 |
| Alcon | 4 | $84 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Revance Therapeutics, Inc. | 1 | $62 |
| Oyster Point Pharma, Inc. | 2 | $56 |
| Amgen(2 entities) | 3 | $55 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $54 |
| Notal Vision, Inc. | 1 | $22 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $21 |
| Vyera Pharmaceuticals, LLC | 1 | $21 |
| Thea Pharma Inc. | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
| Tarsus Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$483,549 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 29 | $36,925 |
| LumiganBimatoprost | 13 | $8,675 |
| Prednisolone Acetate | 155 | $5,230 |
| Alphagan PBrimonidine Tartrate | 15 | $4,660 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $3,803 |
| Difluprednate | 25 | $2,735 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 91 | $896 |
| Latanoprost | 79 | $891 |
| Timolol Maleate | 29 | $614 |
| Ofloxacin | 47 | $460 |
| Dorzolamide Hcl | 20 | $387 |
| Ketorolac Tromethamine | 18 | $347 |
| ErythromycinErythromycin Base | 20 | $206 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 12 | $121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $302 | $50,26057 claims |
| AlconSimbrinza | $84 | $3,80319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Massapequa
- Ketan LaudMassapequa$722K
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.